Apollomics APLM
NASDAQ APLM
$24.33 +0.76 (+3.21%)
As of: Aug 21, 2026 · 3:19 PM EDT

Apollomics (APLM) Accumulated Expenses (2022 - 2025)

Apollomics (APLM) posted quarterly Accumulated Expenses of $6.1 million for Q4 2025, down 52.23% quarter-over-quarter from $12.8 million in Q2 2023.

Apollomics (APLM) Accumulated Expenses (2022 - 2025) Analysis & Trends

Apollomics (APLM) has reported Accumulated Expenses for 3 consecutive years, with $6.1 million the latest figure, recorded in Q4 2025.

  • In Q4 2025, Accumulated Expenses changed N/A year-over-year to $6.1 million; the TTM figure through Dec 2025 stood at $6.1 million (changed N/A YoY), while the FY2025 annual figure was $6.1 million, changed N/A from the prior year.
  • Accumulated Expenses retreated to $6.1 million in Q4 2025 per APLM's latest filing, from $12.8 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $12.8 million in Q2 2023 and bottomed at $6.1 million in Q4 2025.
  • Historically, Accumulated Expenses has averaged $10.2 million across 3 years, with a median of $11.7 million in 2022.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 139.13 Bn 131.28 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.77 Bn 77.77 Bn 3.93 Bn
3 Argenx Se 64.64 Bn 59.46 Bn 1.37 Bn
4 Moderna 58.29 Bn 53.16 Bn 52.00 Mn
5 BeOne Medicines 41.92 Bn 36.82 Bn 1.53 Bn
6 Alnylam Pharmaceuticals 31.58 Bn 28.28 Bn 992.69 Mn
7 BioNTech SE 28.12 Bn 9.73 Bn 668.28 Mn
8 Insmed 27.39 Bn 26.22 Bn 358.27 Mn
9 Royalty Pharma 27.27 Bn 26.43 Bn -
10 Apollomics 35.18 Mn 31.90 Mn -

Historic Data

Download Data
DateValue
Dec 31, 2025 6.12 Mn
Jun 30, 2023 12.80 Mn
Dec 31, 2022 11.68 Mn